Pulmozyme and Divalproex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pulmozyme (dornase alfa) and Divalproex (divalproex sodium). Common drug interactions include infective pulmonary exacerbation of cystic fibrosis among females and gastrointestinal disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Pulmozyme and Divalproex. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Pulmozyme?

Pulmozyme has active ingredients of dornase alfa. It is often used in cystic fibrosis. eHealthMe is studying from 20,012 Pulmozyme users. Check the latest studies of Pulmozyme.

What is Divalproex?

Divalproex has active ingredients of divalproex sodium. It is often used in bipolar disorder. eHealthMe is studying from 14,063 Divalproex users. Check the latest studies of Divalproex.

On Jul, 13, 2026

18 people who take Pulmozyme and Divalproex together, and have interactions are studied.

Pulmozyme and Divalproex drug interactions.

What are the common drug interactions of Pulmozyme and Divalproex, by gender? *:

female:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Attention deficit/hyperactivity disorder
Bacterial infection
Chest discomfort
Diarrhoea
Emotional disorder
Endocarditis (inflammation in heart muscle)
Headache (pain in head)
Sinusitis (inflammation of sinus)
Viral infection

male:

Gastrointestinal disorder (functional problems of gastrointestinal tract)
Nausea (feeling of having an urge to vomit)
Parkinson's disease
Pulmonary function test decreased
Sinus pain
Weight decreased
Abdominal pain upper
Back pain
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Cystic fibrosis pancreatic (fibrosis with cyst in the pancreas)

What are the common drug interactions of Pulmozyme and Divalproex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Sinusitis (inflammation of sinus)

20-29:

Dyspnoea (difficult or laboured respiration)
Pulmonary function test decreased
Weight decreased
Abdominal pain upper
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Chest discomfort
Cystic fibrosis pancreatic (fibrosis with cyst in the pancreas)
Cystic fibrosis related diabetes
Death
Diarrhoea

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Adverse event following immunisation
Dehydration (dryness resulting from the removal of water)
Vomiting
Back pain
Hospitalisation
Feeding disorder (when children refuse to eat certain food groups)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Insomnia (sleeplessness)
Loss of consciousness

* Approximation only. Some reports may have incomplete information.

Do you take Pulmozyme and Divalproex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously